# A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

> **NCT06076642** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 53 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **BIOLOGICAL:** TAK-881
- **DEVICE:** Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)

## Key facts

- **NCT ID:** NCT06076642
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2028-05-16
- **Final completion:** 2028-05-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06076642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06076642, "A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06076642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*